Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product

Thierry Calvez, Hervé Chambost, Patrick Lutz, Chantal Rothschild, Jenny Goudemand

Blood (2015) 125 (24): 3817–3819.

https://doi.org/10.1182/blood-2015-02-622167

Published: 2015

Includes: Supplemental data

Journal Articles

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

Thierry Calvez, Hervé Chambost, Ségolène Claeyssens-Donadel, Roseline d’Oiron, Véronique Goulet, Benoît Guillet, Virginie Héritier, Vanessa Milien, Chantal Rothschild, Valérie Roussel-Robert, Christine Vinciguerra, Jenny Goudemand

Blood (2014) 124 (23): 3398–3408.

https://doi.org/10.1182/blood-2014-07-586347

Published: 2014

Includes: Supplemental data

Journal Articles

Environmental Risk Factors of Inhibitor in Mild/Moderate Hemophilia A Patients Included in the FranceCoag Network

Roseline d'Oiron, MD, Virginie Demiguel, MSc, Annie Borel-Derlon, MD, PhD, Ségolène Donadel-Claeyssens, MD, PhD, Jenny Goudemand, MD, PhD, Benoît Guillet, MD, PhD, Yves Gruel, MD, PhD, Valérie Roussel-Robert, MD, Fabienne Volot, MD, Thierry Calvez, MD, MSc

Blood (2011) 118 (21): 1213.

https://doi.org/10.1182/blood.V118.21.1213.1213

Published: 2011

Journal Articles

Proteolytic antibodies activate factor IX in patients with acquired hemophilia

Bharath Wootla, Olivier D. Christophe, Ankit Mahendra, Jordan D. Dimitrov, Yohann Repessé, Véronique Ollivier, Alain Friboulet, Annie Borel-Derlon, Hervé Levesque, Jeanne-Yvonne Borg, Sebastien Andre, Jagadeesh Bayry, Thierry Calvez, Srinivas V. Kaveri, Sébastien Lacroix-Desmazes

Blood (2011) 117 (7): 2257–2264.

https://doi.org/10.1182/blood-2010-07-296103

Published: 2011

Includes: Supplemental data

Journal Articles

Associations between type of product and inhibitors in previously untreated patients (PUPs) with severe hemophilia: switches and particular products can disturb analysis

Thierry Calvez, Yves Laurian, Jenny Goudemand

Blood (2007) 110 (3): 1073–1074.

https://doi.org/10.1182/blood-2007-03-079723

Published: 2007

Journal Articles

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A

Jenny Goudemand, Chantal Rothschild, Virginie Demiguel, Christine Vinciguerrat, Thierry Lambert, Hervé Chambost, Annie Borel-Derlon, Ségolène Claeyssens, Yves Laurian, Thierry Calvez, the members of the FVIII-LFB and Recombinant FVIII study groups

Blood (2006) 107 (1): 46–51.

https://doi.org/10.1182/blood-2005-04-1371

Published: 2006

NARROW

Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

Environmental Risk Factors of Inhibitor in Mild/Moderate Hemophilia A Patients Included in the FranceCoag Network

Proteolytic antibodies activate factor IX in patients with acquired hemophilia

Associations between type of product and inhibitors in previously untreated patients (PUPs) with severe hemophilia: switches and particular products can disturb analysis

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A

Email alerts

ASH Publications

American Society of Hematology

Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

Environmental Risk Factors of Inhibitor in Mild/Moderate Hemophilia A Patients Included in the FranceCoag Network

Proteolytic antibodies activate factor IX in patients with acquired hemophilia

Associations between type of product and inhibitors in previously untreated patients (PUPs) with severe hemophilia: switches and particular products can disturb analysis

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only